Mesa 2.2. borja garcía cosió
•
1 recomendación•297 vistas
Mesa 2. Control y Biomarcadores en EPOC
![Mesa 2. Control y biomarcadores
[ATS] Do Inhaled
Corticosteroids (ICS)
Reduce Rate Of Decline Of
Lung Function In
COPD Patients With
Eosinophil Count ≥ 2%?
Barnes N, Sharma R, Lettis S,
Calverley PM](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Recomendados
Más contenido relacionado
Destacado
Similar a Mesa 2.2. borja garcía cosió
Similar a Mesa 2.2. borja garcía cosió (20)
Más de FERRER EPOCSITE PRO
Más de FERRER EPOCSITE PRO (20)
Último
Último (20)
Mesa 2.2. borja garcía cosió
- 1. Mesa 2. Control y biomarcadores Dr. Borja García- Cosío Piqueras Hospital Universitario Son Espases. Mallorca
- 2. Mesa 2. Control y biomarcadores [ATS] Do Inhaled Corticosteroids (ICS) Reduce Rate Of Decline Of Lung Function In COPD Patients With Eosinophil Count ≥ 2%? Barnes N, Sharma R, Lettis S, Calverley PM
- 3. Mesa 2. Control y biomarcadores Background and objectives • COPD patients with a blood eosinophil count ≥2 % show a greater reduction in exacerbations when given ICS. • Whether the same is true for rate of decline of lung function is unknown. Pascoe et al. Lancet Resp Med 2015
- 4. Mesa 2. Control y biomarcadores Methods • The results of ISOLDE (FLTB3054) (Burge PS et al BMJ 2000;320:1297–303), a 3-year study of the effects of FP 500mcg twice daily on rate of decline of FEV1 in well-characterised COPD patients were re-analysed by baseline blood eosinophil count (≥2 %, <2 %).
- 5. Mesa 2. Control y biomarcadores Results • Eosinophil count was <2 % in 68 % of patients; the spirometric characteristics of these patients were similar to those with an eosinophil count ≥2 %.
- 6. Mesa 2. Control y biomarcadores Discussion • A baseline blood eosinophil count of ≥2 % identifies a group of COPD patients who show a slower rate of decline of FEV1 when treated with ICSs. Xuan W et al. Am J Resp Crit Care Med 2000
- 7. Mesa 2. Control y biomarcadores [ATS] Human Rhinovirus Infection And CAT Scores During COPD Exacerbations George SN, Mackay AJ, et al.
- 8. Mesa 2. Control y biomarcadores Background and objectives • Human rhinovirus (HRV) is the main aetiological agent of virus-associated COPD exacerbations (Seemungal et al. ARJCCM 2001) • The COPD Assessment Test (CAT) scores have been shown to increase at COPD exacerbation (Mackay et al. AJRCCM 2012). • Authors hypothesized that HRV prevalence and load relate to CAT scores.
- 9. Mesa 2. Control y biomarcadores Methods • Real-time quantitative-PCR was used to assess HRV prevalence and load in sputum samples taken at exacerbation presentation, and during recovery at Days 3, 7, 14, 35 and 56 thereafter. • Exacerbations were defined as an increase in at least two respiratory symptoms for two consecutive days, recorded on prospectively-completed daily diary cards, with at least one symptom being a major symptom; dyspnoea, sputum purulence or volume (Seemungal et al. ARJCCM 1998). • Patients completed a paper version of the CAT diary at each clinic visit based on the symptoms they experienced that day.
- 10. Mesa 2. Control y biomarcadores Results • Sixty-eight patients with moderate to severe COPD (mean age 72.9 years (SD±7.6); stable state FEV1 48.9 % predicted (±19.6 %); FEV1 /FVC 0.46 (±0.1); FEV1 1.18L (±0.5); current smoker 33 %; male gender 63 %) recorded CAT scores for 388 sputum samples taken at different time points during exacerbation and recovery.
- 11. Mesa 2. Control y biomarcadores Discussion • Conclusion: This suggests that exacerbations associated with HRV infection have a greater impact on patient’s health status.
- 12. Mesa 2. Control y biomarcadores Muchas gracias por su atención